Singh Ram B, Fedacko Jan, Mojto Viliam, Pella Dominik
Halbergt Hospital and Research Institute, Moradabad 244001, India.
Department of Internal Medicine, PJ Safaric University, 1040 11 Kosice, Slovakia.
Antioxidants (Basel). 2018 Jul 25;7(8):99. doi: 10.3390/antiox7080099.
The study aims to examine the effects of coenzyme Q10, (a bioenergetic antioxidant), on the indexes of left ventricular remodeling, oxidative damage, and angiotensin-converting enzyme (ACE) level after acute myocardial infarction (AMI) with left ventricular dysfunction. In a double blind, randomized, placebo-controlled, parallel group study (a retrospective analysis of an earlier trial) in 55 patients with left ventricular ejection fraction <50% after AMI, the effects of coenzyme Q10 (120 mg/day) or placebo were studied for 24 weeks. Two-dimensional echocardiography was performed at discharge, (approximately 5⁻10 days after admission) and at 6 months after AMI. The results revealed that wall thickness opposite the site of infarction decreased from (mean ± standard deviation (SD)) 12.2 ± 2.0 mm to 10.0 ± 1.8 mm with coenzyme Q10 compared with 12.8 ± 2.2 mm to 13.3 ± 2.3 mm with placebo ( < 0.01). Left ventricular mass changed from 236 ± 72 g to 213 ± 61 g with coenzyme Q10 compared with 230 ± 77 g to 255 ± 86 g with placebo ( < 0.01). Treatment with coenzyme Q10 also prevented alteration of sphericity index which is a ratio of the long and short axis of the left ventricle (which changed from 1.61 ± 0.28 to 1.63 ± 0.30 with coenzyme Q10 compared with 1.61 ± 0.32 to 1.41 ± 0.31 with placebo ( < 0.05)). Coenzyme Q10 also prevented alteration of the wall thickening abnormality at the infarct site, which changed from 9.4 ± 3.0 cm² to 9.1 ± 2.8 cm² compared with 10.1 ± 3.1 to 13.7 ± 4.2 cm² with placebo ( < 0.05). End diastolic and systolic volumes also showed significant reduction with coenzyme Q10 compared to placebo. The serum level of ACE showed significant decline in the coenzyme Q10 group compared to the control group. Treatment with coenzyme Q10 early after AMI causes attenuation of left ventricular remodeling and decreases the serum ACE level in patients with left ventricular dysfunction.
本研究旨在探讨辅酶Q10(一种生物能量抗氧化剂)对急性心肌梗死(AMI)合并左心室功能障碍患者左心室重构、氧化损伤及血管紧张素转换酶(ACE)水平指标的影响。在一项针对55例AMI后左心室射血分数<50%患者的双盲、随机、安慰剂对照、平行组研究(对一项早期试验的回顾性分析)中,研究了辅酶Q10(120毫克/天)或安慰剂治疗24周的效果。在出院时(入院后约5 - 10天)及AMI后6个月进行二维超声心动图检查。结果显示,与安慰剂组相比,辅酶Q10组梗死部位对侧的室壁厚度从(均值±标准差(SD))12.2±2.0毫米降至10.0±1.8毫米,而安慰剂组从12.8±2.2毫米增至13.3±2.3毫米(P<0.01)。辅酶Q10组左心室质量从236±72克变为213±61克,安慰剂组从230±77克变为255±86克(P<0.01)。辅酶Q10治疗还可防止球形指数改变,球形指数是左心室长轴与短轴之比(辅酶Q10组从1.61±0.28变为1.63±0.30,安慰剂组从1.61±0.32变为1.41±0.31,P<0.05)。辅酶Q10还可防止梗死部位室壁增厚异常改变,辅酶Q10组从9.4±3.0平方厘米变为9.1±2.8平方厘米,安慰剂组从10.1±3.1变为13.7±4.2平方厘米(P<0.05)。与安慰剂相比,辅酶Q10组舒张末期和收缩末期容积也显著降低。与对照组相比,辅酶Q10组血清ACE水平显著下降。AMI后早期使用辅酶Q10治疗可减轻左心室重构,并降低左心室功能障碍患者的血清ACE水平。